Fig. 2: Analysis of B cells and plasma cells from patients given LD IL-2 treatment.
From: Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells
a Diagrammatic schema summarizing the two treatment arms of the LD aldesleukin study. Patients with recently-diagnosed type 1 diabetes received 0.09 × 106 IU/m2 or 0.2–0.47 × 106 IU/m2 aldesleukin every two to five days. Proportion (of total B cells) or absolute number of IL-10-positive B cells in patients prior to and following the administration of 0.09 × 106 IU/m2 (c) or 0.2–0.47 × 106 IU/m2 (d) aldesleukin. Coloured line indicates mean changes following treatment. Representative flow cytometry plot of IL-10 expressing B cells pre- and post- 0.09 × 106 IU/m2 (b) or 0.2–0.47 × 106 IU/m2 (e) aldesleukin. p-values generated using a paired two-tailed parametric t-test. *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source Data file.
